Eiger BioPharmaceuticals to Present at the H.C. Wainwright Third Annual Hepatitis B Virus (HBV) Virtual Conference
A live webcast of the presentation will be available on the Investors section of the
Eiger is a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases. The Eiger HDV platform includes two first-in-class therapies in Phase 3 that target critical host processes involved in viral replication. All five Eiger rare disease programs have been granted FDA Breakthrough Therapy designation: lonafarnib/ritonavir for HDV, peginterferon lambda for HDV, avexitide for congenital hyperinsulinism, avexitide for post-bariatric hypoglycemia, and Zokinvy® (lonafarnib) for progeria.
For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
Contacts
Investors:
[email protected]
Media:
SVP, Corporate Affairs
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-present-at-the-hc-wainwright-third-annual-hepatitis-b-virus-hbv-virtual-conference-301645595.html
SOURCE